Circulating Tumor DNA Market Size to Surge USD 27.67 Billion by 2034

Circulating Tumor DNA Market Highlights

• North America dominated the circulating tumor DNA (ctDNA) market with a 51% share in 2024.
• Asia Pacific is expected to grow at the fastest CAGR from 2025 to 2034.
• By technology, the next-generation sequencing (NGS) segment contributed the largest market share of 48% in 2024.
• By technology, the PCR-based assays segment is expected to grow at a significant CAGR over the forecast period.
• By application, the cancer diagnosis and screening segment led the market while holding the largest share of 53% in 2024.
• By application, the minimal residual disease (MRD) monitoring segment is expected to grow at the fastest CAGR from 2025 to 2034.
• By sample test, the blood segment led the market while holding the largest share of 82% in 2024.
• By sample test, the urine segment is expected to grow at a significant CAGR between 2025 and 2034.
• By end-user, the clinical laboratories & diagnostic centers segment led the market while holding the largest share of 51% in 2024.
• By end-user, the biopharma companies segment is expected to grow at the highest CAGR between 2025 and 2034.

Market Overview

The circulating tumor DNA (ctDNA) market represents a transformative segment of the oncology diagnostics landscape, leveraging non-invasive liquid biopsy approaches to detect and monitor cancer at the molecular level. ctDNA refers to small DNA fragments released into the bloodstream by apoptotic or necrotic tumor cells, providing valuable genetic insights without the need for traditional tissue biopsies.

This technology enables early cancer detection, real-time monitoring of treatment response, and identification of minimal residual disease (MRD) — critical factors in guiding personalized cancer care. With rising global cancer incidence, particularly lung, colorectal, and breast cancers, and the growing clinical validation of ctDNA assays, demand is accelerating across hospitals, diagnostic laboratories, and research institutions.

Advancements in next-generation sequencing (NGS), digital PCR, and AI-powered bioinformatics are improving ctDNA detection sensitivity, enabling earlier and more accurate clinical decisions. The growing adoption of liquid biopsies is also enhancing the feasibility of population-level cancer screening and recurrence monitoring. The VICTORI study, showcased at the AACR 2025, reinforced ctDNA’s potential to detect colorectal cancer recurrence more than a year before conventional imaging, highlighting its transformative role in precision oncology.

Key Technological Shifts in the Circulating Tumor DNA (ctDNA) Industry

The circulating tumor DNA (ctDNA) industry is undergoing a major technological transformation driven by rapid advancements in sequencing and molecular diagnostics. High-sensitivity detection methods such as next-generation sequencing (NGS) and digital PCR (dPCR) have significantly improved the ability to identify low-frequency mutations, enabling earlier cancer detection and more precise monitoring of treatment responses. The growing adoption of non-invasive liquid biopsy platforms is revolutionizing cancer care by replacing traditional tissue biopsies with blood-based tests that allow real-time tracking of tumor dynamics and therapy effectiveness. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) into ctDNA data analysis is enhancing accuracy by enabling advanced mutation profiling, pattern recognition, and predictive modeling for personalized oncology.

Furthermore, the industry is shifting toward multi-cancer early detection (MCED) assays that utilize ctDNA methylation and fragmentomics to identify multiple cancer types from a single blood sample, accelerating early diagnosis and intervention. Automation and digitalization are also streamlining workflows, with cloud-based bioinformatics platforms standardizing ctDNA testing and reducing turnaround times. Meanwhile, the development of cost-effective, microfluidic, and point-of-care ctDNA solutions is making precision diagnostics more accessible in both advanced and emerging healthcare markets. Collectively, these innovations are transforming ctDNA testing into a cornerstone of precision oncology—enabling earlier detection, continuous monitoring, and personalized treatment strategies for improved patient outcomes.